Effects of dendritic cells transfected with full length wild-type p53 and modified by bile duct cancer lysates on immune response

Hepatobiliary and Pancreatic Diseases International

Volumn 4, Issue 1, 2005, Pages 121-125

  Sun, Huan Wen ^a   Tang, Qi Bing ^b   Tang, Chong ^b   Zou, Sheng Quan ^b  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Bile duct cancer; Dendritic cells; Full length wild type p53; Lymphocytes; Lysate

Indexed keywords

ADENOVIRUS VECTOR; B7 ANTIGEN; CD86 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE DUCT CANCER; CANCER IMMUNOTHERAPY; CELL LYSATE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC TRANSFECTION; IMMUNE RESPONSE; MOUSE; NONHUMAN; TUMOR VOLUME; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; BILE DUCT NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; FEMALE; GENES, P53; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, INBRED BALB C; SENSITIVITY AND SPECIFICITY; TISSUE EXTRACTS; TRANSFECTION; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 14844299788     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Huang A, Gilmour JW, Imami N, Amjadi P, Henderson DC, Allen-Mersh TG. Increased serum transforming growth factor-beta1 in human colorectal cancer correlates with reduced circulating dendritic cells and increased colonic Langerhans cell infiltration. Clin Exp Immunol 2003;134:270-278.
2. Syme RM, Duggan P, Stewart D, Gluck S. Generation of dendritic cells ex vivo: differences in steady state versus mobilized blood from patients with breast cancer, with lymphoma, and from normal donors. J Hematother Stem Cell Res 2001;10: 621-630.
3. Brostjan C, Bayer A, Zommer A, Gomikiewicz A, Roka S, Benko T, et al. Monitoring of circulating angiogenic factors in dendritic cell-based cancer immunotherapy. Cancer 2003;98: 2291-2301.
4. Foley R, Tozer R, Wan Y. Genetically modified dendritic cells in cancer therapy: implications for transfusion medicine. Transfus Med Rev 2001;15:292-304.
5. Hikino H, Kasono K, Kanzaki M, Kai T, Konishi F, Kawakami M. Granulocyte/macrophage colony-stimulating factor and interleukin-4-induced dendritic cells. Anticancer Res 2004;24: 1609-1615.
6. Levy B, Panicalli D, Marshall J. TRICOM: enhanced vaccines as anticancer therapy. Expert Rev Vaccines 2004;3:397-402.
7. Treilleux I, Blay JY, Bendriss-Vermare N, Ray-Coquard I, Bachelot T, Guastalla JP, et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res 2004; 10:7466-7474.
8. Klein C, Bueler H, Mulligan RC. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J Exp Med 2000;191:1699-1708.
9. Morse MA, Lyerly HK. Dendritic cell-based immunization for cancer therapy. Adv Exp Med Biol 2000;465:335-346.
10. Ragde H, Cavanagh WA, Tjoa BA. Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer. J Urol 2004;17:2532-2538.
11. Esche C, Shurin MR, Lotze MT. The use of dendritic cells for cancer vaccination. Curr Opin Mol Ther 1999;1:72-81.
12. Tjoa BA, Lodge PA, Salgaller ML, Boynton AL, Murphy GP. Dendritic cell-based immunotherapy for prostate cancer. CA Cancer J Clin 1999;49:117-128.
13. Bubenik J. Dendritic-cell-based cancer vaccines. Folia Biol (Praha) 1999;45:71-74.
14. Ahmed SU, Okamoto M, Oshikawa T, Tano T, Sasai A, Kan S, et al. Anti-tumor effect of an intratumoral administration of dendritic cells in combination with TS-1, an oral fluoropyrimidine anti-cancer drug, and OK-432, a streptococcal immunopotentiator: involvement of toil-like receptor 4. J Immunother 2004;27:432-441.
15. Koido S, Ohana M, Lin C, Nikrui N, Durfee J, Lerner A, et al. Dendritic cells fused with human cancer cells: morphology, antigen expression, and T cell stimulation. Clin Immunol 2004;113:261-269.
16. Lyerly HK, Morse MA. Carcinoembryonic antigen peptide-pulsed dendritic cells in patients with metastatic cancer. Clin Lung Cancer 1999;1:700-702.
17. Markiewicz MA, Kast WM. Progress in the development of immunotherapy of cancer using ex vivo-generated dendritic cells expressing multiple tumor antigen epitopes. Cancer Invest 2004;22:417-434.
18. Kalady MF, Onaitis MW, Emani S, Abdul-Wahab Z, Pruitt SK, Tyler DS. Dendritic cells pulsed with pancreatic cancer total tumor RNA generate specific antipancreatic cancer T cells. J Gastrointest Surg 2004;8:175-181.
19. Ueda Y, Itoh T, Nukaya I, Kawashima I, Okugawa K, Yano Y, et al. Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas. Int J Oncol 2004;24:909-917.
20. Mu LJ, Gaudemack G, Saeboe-Larssen S, Hammerstad H, Tierens A, Kvalheim. G. A protocol for generation of clinical grade mRNA-transfected monocyte-derived dendritic cells for cancer vaccines. Stand J Immunol 2003;58:578-586.
21. Babatz J, Rollig C, Oelschlagel U, Zhao S, Ehninger G, Schmitz M, et al. Large-scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: a phase I study. J Hematother Stem Cell Res 2003; 12:515-523.
22. Della Bella S, Geunaro M, Vaccari M, Ferrafis C, Nicola S, Riva A, et al. Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer 2003;89:1463-1472.
23. Brossart P, Wirths S, Brugger W, Kanz L. Dendritic cells in cancer vaccines. Exp Hematol 2001;29:1247-1255.
24. Bubenik J. Genetically modified dendritic cell-based cancer vaccines. Folia Biol (Praha) 2001;47:153-155.
25. Suzuki Y, Yanagawa H, Nishioka Y, Nishimura N, Takeuchi E, Sone, S. Efficient generation of dendritic cells from alveolar and pleural macrophages as well as blood monocytes in patients with lung cancer. Lung Cancer 2001;34:195-205.
26. Lissoni P, Brivio F, Ferrante R, Vigore L, Vaghi M, Fumagalli E, et al. Circulating immature and mature dendritic cells in relation to lymphocyte subsets in patients with gastrointestinal tract cancer. Int J Biol Markers 2000;15:22-25.
27. Gunzer M, Grabbe S. Dendritic cells in cancer immunotherapy. Crit Rev Immunol 2001;21:133-145.
28. Nencioni A, Brossart P. New perspectives in dendritic cell-based cancer immunotherapy. BioDrugs 2001;15:667-679.
29. Sprinzl GM, Kacani L, Schrott-Fischer A, Romani N, Thumfart WF. Dendritic cell vaccines for cancer therapy. Cancer Treat Rev 2001;27:247-255.
30. Schreurs MW, Eggert AA, Punt CJ, Figdor CG, Adema GJ. Dendritic cell-based vaccines: from mouse models to clinical cancer immunotherapy. Crit Rev Oncog 2000;11:11-17.